A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.